Trial Profile
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Olokizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms CREDO 1
- Sponsors R-Pharm
- 15 Nov 2023 Results (n=1944) assessing the changes in serum adiponectin levels in patients with active rheumatoid arthritis during treatment with IL-6 inhibitor olokizumab from NCT02760368; NCT02760407; NCT02760433 trials, presented at the ACR Convergence 2023.
- 03 Aug 2021 Results published in the Annals of the Rheumatic Diseases
- 06 Jun 2020 Primary endpoint (American College of Rheumatology 20% (ACR20) response at week 12: American College of Rheumatology 20% (ACR20) response at week 12: Olokizumab (OKZ) 64 mg q2w, OKZ 64 mg q4w versus PBO q2w ) has been met, according to results presented at the 21st Annual Congress of the European League Against Rheumatism.